ImmunityBio Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning to ImmunityBio, stating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast regarding the company's lead biologic product, Anktiva, asserting it could 'cure and prevent all cancer,' exposing the company to legal risks.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors' asset values and resulted in significant losses.
- Class Action Context: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the true capabilities of Anktiva, which may mislead investors about the company's prospects and affect future investment decisions.
- Investor Action Notice: Investors are reminded to file their lead plaintiff motions by May 26, 2026, to seek compensation for their investment losses, highlighting the importance of timely action in the legal process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.600
Low
5.00
Averages
7.33
High
9.00
Current: 7.600
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Class Action Reminder for Investors
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning to ImmunityBio, stating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast regarding the company's lead biologic product, Anktiva, asserting it could 'cure and prevent all cancer,' exposing the company to legal risks.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors' asset values and resulted in significant losses.
- Class Action Context: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the true capabilities of Anktiva, which may mislead investors about the company's prospects and affect future investment decisions.
- Investor Action Notice: Investors are reminded to file their lead plaintiff motions by May 26, 2026, to seek compensation for their investment losses, highlighting the importance of timely action in the legal process.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Timeline: Investors must file Lead Plaintiff applications by May 26, 2026, to participate in the securities class action against ImmunityBio, covering stock transactions from January 19 to March 24, 2026, highlighting investor concerns over potential losses.
- FDA Warning Impact: Following a March 13, 2026, warning letter from the FDA indicating misleading advertising for Anktiva, ImmunityBio's stock price plummeted by 21% or $1.98 per share on March 24, 2026, demonstrating the direct impact of regulatory risks on the company's valuation.
- Legal Accountability: The lawsuit alleges that ImmunityBio and its executives failed to disclose material information during the class period, violating federal securities laws, indicating significant deficiencies in the company's transparency that could lead to severe legal repercussions.
- Investor Rights Protection: Kahn Swick & Foti law firm urges affected investors to contact their managing partner to understand their legal rights, emphasizing the importance of seeking compensation in securities fraud cases, reflecting a commitment to protecting investor interests.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that may lead to further investor losses.
- False Advertising Issues: The FDA noted that ImmunityBio's claims in advertisements and podcasts suggesting Anktiva could treat all cancers lack supporting data and fail to provide complete information regarding the drug's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, reflecting a strong commitment to investor rights and demands for corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Berger Montague has filed a class action lawsuit against ImmunityBio on behalf of investors who purchased shares between January 19 and March 24, 2026, indicating a significant loss of confidence in the company's future prospects.
- Significant Investor Losses: The lawsuit alleges that Chief Scientific Officer Patrick Soon-Shiong materially overstated the performance of the Anktiva platform, resulting in a more than 21% drop in share price in a single trading session, causing heavy losses for investors.
- Investor Deadline: Investors must seek to be appointed as lead plaintiff representatives by May 26, 2026, highlighting the urgency of the legal process and the necessity for investor advocacy.
- Law Firm Background: Berger Montague specializes in complex civil litigation and class actions, having recovered over $50 billion for clients over the past 55 years, demonstrating its strong capabilities and influence in the legal field.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation, indicating potential legal risks that may undermine shareholder confidence in the company.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, which underscores the firm's expertise and experience in such cases, potentially influencing the outcome positively.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, raising concerns about the accuracy and completeness of information provided to investors, which could undermine investor confidence.
- Lawsuit Allegations: A complaint filed on March 26, 2026, against ImmunityBio and its executives alleges that Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects, potentially impacting stock prices.
- Investor Losses: Attorney Andrea Farah stated that investors who suffered losses exceeding $50,000 in ImmunityBio securities are encouraged to participate in the investigation, which may lead to more investors seeking legal remedies, further exacerbating the company's legal risks.
- Firm Background: Lowey Dannenberg is a national law firm representing investors who have suffered financial losses due to corporate fraud and malfeasance, with significant experience in prosecuting multi-million-dollar lawsuits, which could have a substantial impact on ImmunityBio's future.
See More
ImmunityBio Class Action Reminder for Investors
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning to ImmunityBio, stating that Executive Chairman Patrick Soon-Shiong made false claims on a podcast regarding the company's lead biologic product, Anktiva, asserting it could 'cure and prevent all cancer,' exposing the company to legal risks.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, which directly impacted investors' asset values and resulted in significant losses.
- Class Action Context: The class action lawsuit alleges that the company made materially false and misleading statements during the class period, failing to disclose the true capabilities of Anktiva, which may mislead investors about the company's prospects and affect future investment decisions.
- Investor Action Notice: Investors are reminded to file their lead plaintiff motions by May 26, 2026, to seek compensation for their investment losses, highlighting the importance of timely action in the legal process.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- Lawsuit Timeline: Investors must file Lead Plaintiff applications by May 26, 2026, to participate in the securities class action against ImmunityBio, covering stock transactions from January 19 to March 24, 2026, highlighting investor concerns over potential losses.
- FDA Warning Impact: Following a March 13, 2026, warning letter from the FDA indicating misleading advertising for Anktiva, ImmunityBio's stock price plummeted by 21% or $1.98 per share on March 24, 2026, demonstrating the direct impact of regulatory risks on the company's valuation.
- Legal Accountability: The lawsuit alleges that ImmunityBio and its executives failed to disclose material information during the class period, violating federal securities laws, indicating significant deficiencies in the company's transparency that could lead to severe legal repercussions.
- Investor Rights Protection: Kahn Swick & Foti law firm urges affected investors to contact their managing partner to understand their legal rights, emphasizing the importance of seeking compensation in securities fraud cases, reflecting a commitment to protecting investor interests.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that may lead to further investor losses.
- False Advertising Issues: The FDA noted that ImmunityBio's claims in advertisements and podcasts suggesting Anktiva could treat all cancers lack supporting data and fail to provide complete information regarding the drug's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, reflecting a strong commitment to investor rights and demands for corporate transparency.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Initiated: Berger Montague has filed a class action lawsuit against ImmunityBio on behalf of investors who purchased shares between January 19 and March 24, 2026, indicating a significant loss of confidence in the company's future prospects.
- Significant Investor Losses: The lawsuit alleges that Chief Scientific Officer Patrick Soon-Shiong materially overstated the performance of the Anktiva platform, resulting in a more than 21% drop in share price in a single trading session, causing heavy losses for investors.
- Investor Deadline: Investors must seek to be appointed as lead plaintiff representatives by May 26, 2026, highlighting the urgency of the legal process and the necessity for investor advocacy.
- Law Firm Background: Berger Montague specializes in complex civil litigation and class actions, having recovered over $50 billion for clients over the past 55 years, demonstrating its strong capabilities and influence in the legal field.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Action Call: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation, indicating potential legal risks that may undermine shareholder confidence in the company.
- Law Firm Background: The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally, which underscores the firm's expertise and experience in such cases, potentially influencing the outcome positively.
See More
Lowey Dannenberg Investigates ImmunityBio for Potential Securities Violations
- Legal Investigation Launched: Lowey Dannenberg P.C. is investigating ImmunityBio Inc. for potential violations of federal securities laws, raising concerns about the accuracy and completeness of information provided to investors, which could undermine investor confidence.
- Lawsuit Allegations: A complaint filed on March 26, 2026, against ImmunityBio and its executives alleges that Soon-Shion materially overstated Anktiva's capabilities, resulting in materially false and misleading statements about the company's business and prospects, potentially impacting stock prices.
- Investor Losses: Attorney Andrea Farah stated that investors who suffered losses exceeding $50,000 in ImmunityBio securities are encouraged to participate in the investigation, which may lead to more investors seeking legal remedies, further exacerbating the company's legal risks.
- Firm Background: Lowey Dannenberg is a national law firm representing investors who have suffered financial losses due to corporate fraud and malfeasance, with significant experience in prosecuting multi-million-dollar lawsuits, which could have a substantial impact on ImmunityBio's future.
See More
